Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.82 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.82 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.70 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329302 | 0.92 | PIK3CG (0.86) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL22440914 | 0.92 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL22440990 | 0.91 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL19347978 | 0.91 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL22440949 | 0.90 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL29099511 | 0.87 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL19329781 | 0.85 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL19995220 | 0.84 | PIK3CG (0.84) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL19995222 | 0.84 | PIK3CG (0.84) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B | |
| SCHEMBL22723117 | 0.83 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779110-B | Novel inhibitors of phosphatidylinositol 3-kinase gamma | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | claimed |
| EP-3426652-B1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| CN-108779110-B | Novel inhibitors of phosphatidylinositol 3-kinase gamma | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PIK3CD, PIK3CG, PIK3CA | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 18/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | PIK3CG 2/4885PIK3CD 1/4885PIK3R1 18/4885 |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PI4KA, PIK3CD, PI4KB | PIK3CG 4/4885PIK3CD 2/4885PIK3R1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.